Q2 2025 Earnings Call Transcript August 18, 2025 Nyxoah S.A. misses on earnings expectations. Reported EPS is $-0.63 EPS, ...

Nyxoah gains FDA approval for its Genio system, signaling a major growth milestone. Explore revenue growth, risks, and why ...

Pre-Market Approval (PMA) for the Genio system, the first and only bilateral hypoglossal neurostimulation therapy approved in ...

This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .

After years of being cleared on the European market, Nyxoah’s neuromodulation therapy for obstructive sleep apnea has now ...

Nyxoah ( ($NYXH) ) has provided an update. On August 18, 2025, Nyxoah SA announced its financial and operating results for the second quarter and ...

The FDA has approved the Genio system for the treatment of patients with moderate to severe obstructive sleep apnea.

Nyxoah SA (NASDAQ:NYXH) is set to release its Q2 2025 earnings on Aug 18, 2025. The consensus estimate for Q2 2025 revenue is ...

Nyxoah Reports Fourth Quarter and Financial Year 202 4 Financial and Operating Results FDA PMA Application Review Nearing Conclusion Positioned for U.S. Commercial Launch in March 2025. Revenue ...

Analysts estimate that Nyxoah will report an earnings per share (EPS) of $-0.63. Nyxoah bulls will hope to hear the company ...

Nyxoah announced today that it received FDA approval for its Genio neuromodulation device for treating sleep apnea.

Nyxoah said the FDA approved the company's Genio system for a subset of patients with moderate to severe obstructive sleep apnea. The system includes a wearable component, which provides patients with ...